Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.
Bronchiectasis is a disease of renewed interest in light of an increase in prevalence and increasing burden on international healthcare systems. There are no licensed therapies, and large gaps in knowledge in terms of epidemiology, pathophysiology and therapy. The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) is a European Respiratory Society (ERS) Clinical Research Collaboration, funded by ERS to promote high-quality research in bronchiectasis. The objective of this consensus statement was to define research priorities in bronchiectasis. From 2014 to 2015, EMBARC used a modified Delphi process among European bronchiectasis experts to reach a consensus on 55 key research priorities in this field. During the same period, the European Lung Foundation collected 711 questionnaires from adult patients with bronchiectasis and their carers from 22 European countries reporting important research priorities from their perspective. This consensus statement reports recommendations for bronchiectasis research after integrating both physicians and patients priorities, as well as those uniquely identified by the two groups. Priorities identified in this consensus statement provide the clearest possible roadmap towards improving our understanding of the disease and the quality of care for patients with bronchiectasis.
Dept of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy stefano.aliberti@unimi.it.
Stefano
S
Aliberti
European Lung Foundation, Sheffield, UK.
Sarah
S
Masefield
Fundaciò Clìnic, IDIBAPS, CIBERES, Hospital Clinic de Barcelona, Barcelona, Spain.
Eva
E
Polverino
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Bronchiectasis Service, Freeman Hospital, Newcastle upon Tyne, UK.
Anthony
A
De Soyza
Host Defence Unit, Royal Brompton Hospital, London, UK.
Michael R
MR
Loebinger
Pneumology Service, Universitary and Polytechnic Hospital La Fe, Valencia, Spain.
Rosario
R
Menendez
Dept of Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany.
Felix C
FC
Ringshausen
Bronchiectasis Group, Girona Biomedical Research Institute (IDIBGI), Dr. Trueta University Hospital, Girona, Spain.
Montserrat
M
Vendrell
European Lung Foundation, Sheffield, UK.
Pippa
P
Powell
College of Medicine, University of Dundee, Dundee, UK.
James D
JD
Chalmers
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D018070:Biological Specimen Banks; D035843:Biomedical Research / Q000639:trends*; D001987:Bronchiectasis / Q000175:diagnosis* / Q000453:epidemiology; D002986:Clinical Trials as Topic; D032921:Consensus; D003697:Delphi Technique; D005060:Europe; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D015995:Prevalence; D011795:Surveys and Questionnaires
D000900:Anti-Bacterial Agents